Back to News
Market Impact: 0.2
Teva Pharmaceutical Industries Limited - Depositary Receipt Price Target Increased by 35.74% to $0.15
Source: Nasdaq
Analyst EstimatesAnalyst Insights
The average one-year price target for Teva Pharmaceutical Industries Limited depositary receipts (NYSE: TEVA) was revised to $0.15 per share, up 35.74% from the prior $0.11 estimate dated October 22, 2026. The article describes the figures as an aggregation of analysis; no price reaction or further context is provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
TEVA0.20
More News
- Neurocrine earnings in focus as Ingrezza pricing pressure looms
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- Reliance’s Record $19 Billion Surge Lifts Nifty, Keeps India Bulls in the Game
- Apple reports after the bell. Options traders expect a big move
- Why is Apple stock falling afterhours today?
- Mizuho lowers Lumentum stock price target on Marvell acquisition